Loading
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
Previous close
$14.41
+$0.41 · +2.93%
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
32
Expensive
Sentiment
50
Mixed
Risk
47
Elevated Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
Day range
Current $14.41
52-week range
Current $14.41
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 1.23M USD | — | — | — | — |
| Gross profit | −1.23M USD | — | — | — | — |
| Research and development | 30.83M USD | 27.02M USD | 26.42M USD | 20.89M USD | 11.45M USD |
| Selling, general, and administrative | 10.22M USD | 9.02M USD | 9.26M USD | 11.25M USD | 2.34M USD |
| Operating expenses | 41.06M USD | 36.04M USD | 35.68M USD | 32.14M USD | 13.79M USD |
| Interest income | 3.84M USD | 4.28M USD | 4.83M USD | 1.79M USD | 211K USD |
| Interest expense | 419K USD | 303K USD | 75K USD | — | — |
| Depreciation and amortization | 1.23M USD | 1.1M USD | 1.07M USD | 979K USD | 776K USD |
| Operating income | −42.29M USD | −36.04M USD | −35.68M USD | −32.14M USD | −13.79M USD |
| Net income | −42.63M USD | −31.75M USD | −29.16M USD | −33.76M USD | −27.27M USD |
Company facts updated Oct 11, 2026.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
